Hdl Handle:
http://hdl.handle.net/10147/206211
Title:
Palivizumab use in preterm neonates.
Authors:
Kingston, S; Murphy, B P
Affiliation:
Department of Neonatology, Cork University Maternity Hospital, Wilton, Cork.
Citation:
Ir Med J. 2010 May;103(5):141-4.
Journal:
Irish medical journal
Issue Date:
31-Jan-2012
URI:
http://hdl.handle.net/10147/206211
PubMed ID:
20666085
Abstract:
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal units in Ireland. A questionnaire was administered to one Consultant Neonatologist or Paediatrician in each of the 20 maternity centres in Ireland about their guidelines for Palivizumab administration. There is variation in administration of Palivizumab with little consistency found between protocols reported in terms of age and presence of chronic lung disease. Ten centres have in house protocols, 3 centres use the American Academy of Paediatrics (AAP) guidelines, 2 centres prefer the UK Joint Committee on Vaccination and Immunisation (JCVI) guidelines and 3 centres do not have a set protocol. Four participants felt its use has impacted on hospital admissions and 61% believe its use is cost effective. The budgetary implication for immunoprophylaxis with Palivizumab in Ireland is estimated at 1.5 to 2 million euros annually. Given current pharmacoeconomic constraints there is a need to implement a national protocol on RSV immunoprophylaxis.
Language:
eng
MeSH:
Antibodies, Monoclonal/*therapeutic use; Antibodies, Monoclonal, Humanized; Antiviral Agents/*therapeutic use; Bronchiolitis/*prevention & control/virology; Clinical Protocols; Female; Guideline Adherence; Humans; Infant, Newborn; *Infant, Premature; Ireland; Male; Physician's Practice Patterns/*statistics & numerical data; Questionnaires; Respiratory Syncytial Virus Infections/*prevention & control
ISSN:
0332-3102 (Print); 0332-3102 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKingston, Sen_GB
dc.contributor.authorMurphy, B Pen_GB
dc.date.accessioned2012-01-31T16:43:43Z-
dc.date.available2012-01-31T16:43:43Z-
dc.date.issued2012-01-31T16:43:43Z-
dc.identifier.citationIr Med J. 2010 May;103(5):141-4.en_GB
dc.identifier.issn0332-3102 (Print)en_GB
dc.identifier.issn0332-3102 (Linking)en_GB
dc.identifier.pmid20666085en_GB
dc.identifier.urihttp://hdl.handle.net/10147/206211-
dc.description.abstractRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal units in Ireland. A questionnaire was administered to one Consultant Neonatologist or Paediatrician in each of the 20 maternity centres in Ireland about their guidelines for Palivizumab administration. There is variation in administration of Palivizumab with little consistency found between protocols reported in terms of age and presence of chronic lung disease. Ten centres have in house protocols, 3 centres use the American Academy of Paediatrics (AAP) guidelines, 2 centres prefer the UK Joint Committee on Vaccination and Immunisation (JCVI) guidelines and 3 centres do not have a set protocol. Four participants felt its use has impacted on hospital admissions and 61% believe its use is cost effective. The budgetary implication for immunoprophylaxis with Palivizumab in Ireland is estimated at 1.5 to 2 million euros annually. Given current pharmacoeconomic constraints there is a need to implement a national protocol on RSV immunoprophylaxis.en_GB
dc.language.isoengen_GB
dc.subject.meshAntibodies, Monoclonal/*therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Humanizeden_GB
dc.subject.meshAntiviral Agents/*therapeutic useen_GB
dc.subject.meshBronchiolitis/*prevention & control/virologyen_GB
dc.subject.meshClinical Protocolsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshGuideline Adherenceen_GB
dc.subject.meshHumansen_GB
dc.subject.meshInfant, Newbornen_GB
dc.subject.mesh*Infant, Prematureen_GB
dc.subject.meshIrelanden_GB
dc.subject.meshMaleen_GB
dc.subject.meshPhysician's Practice Patterns/*statistics & numerical dataen_GB
dc.subject.meshQuestionnairesen_GB
dc.subject.meshRespiratory Syncytial Virus Infections/*prevention & controlen_GB
dc.titlePalivizumab use in preterm neonates.en_GB
dc.contributor.departmentDepartment of Neonatology, Cork University Maternity Hospital, Wilton, Cork.en_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.